Gregory O. Anglum bought BVS once, on Feb 11, 2021

Gregory O. Anglum is a corporate finance executive and former Senior Vice President, Chief Financial Officer and Principal Accounting Officer of Bioventus Inc., a medical technology company focused on orthobiologic solutions.( As a corporate insider at Bioventus (Nasdaq: BVS), he oversaw financial strategy, accounting, business intelligence and IT, contributing to the company’s growth, capital markets activity, and leadership transitions.( He later became a named defendant in shareholder litigation involving Bioventus, reflecting his role and responsibilities as a senior officer of the company.(

Anglum joined Bioventus in 2016 as Chief Accounting Officer and was promoted to SVP and CFO in 2017, bringing more than 20 years of experience in finance and strategy for both private and public companies.( Before Bioventus, he held CFO roles at technology and SaaS firms including Overture and StrikeIron, and began his career in public accounting at Arthur Andersen and Grant Thornton.( He holds a BA in Economics from Vanderbilt University and an MBA from Vanderbilt’s Owen Graduate School of Management, and is a Certified Public Accountant and Chartered Global Management Accountant.( More recently, his career has continued in healthcare and life sciences finance leadership, including CFO roles at restor3d and BioTouch.(

Written by Perplexity from public sources.